Product Theaters Product Theaters, located in the rear of the Exhibit Hall, offer informative sessions focusing on particular products or a single facet of diabetes. Product Theater sessions do not provide continuing education credit. These sessions are intended for health care professionals only with practices relevant to the presented information. We regret that spouses and other guests cannot be accommodated. Light refreshments provided by the American Diabetes Association will be served to the first 300 attendees. SATURDAY, JUNE 11 12:15 p.m. 1:15 p.m. Options in Basal Insulin Basaglar (Insulin Glargine Injection) Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly USA, LLC This program will discuss an FDA-approved insulin glargine option from the Boehringer Ingelheim and Eli Lilly and Company Alliance. The presentation will provide information regarding the Basaglar clinical profile, as well as dosing and administration. Attendees will have the opportunity to ask the faculty questions about the data presented. Thomas C. Blevins, MD Endocrinologist Texas Diabetes & Endocrinology Dallas, TX 12:15 p.m. 1:15 p.m. The Role of a Once-Weekly GLP-1 RA Therapy in Improving Glucose Control Sponsored by AstraZeneca This presentation will demonstrate how glucose profiles differ amongst patients with type 2 diabetes and the opportunity to manage glucose fluctuations. The content includes a review of a study that evaluated a specific glucagon-like-peptide-1 receptor agonist (GLP-1 RA) therapy using continuous glucose monitoring (CGM) to determine its effect on 24-hour glucose control in patients with type 2 diabetes. Additionally, efficacy of this Once-Weekly GLP-1RA proven in a series of clinical trials that showed both short- and long-term efficacy will also be presented. Concluding the program will be information on the proper device preparation and administration of this Once-Weekly GLP-1 RA therapy. Helena W. Rodbard, MD, FACP, MACE Endocrine and Metabolic Consultants Rockville, MD
2:45 p.m. 3:30 p.m. Toujeo (Insulin Glargine Injection 300 Units/mL) A Once Daily Basal Insulin Clinical Overview and Features Toujeo (insulin glargine injection) 300 Unit/mL is a long-acting basal insulin indicated to improve glycemic control in adult patients with diabetes mellitus. This presentation is intended to provide clinicians with a comprehensive overview of Toujeo, including the pharmacologic profile and data from 4 EDITION clinical trials carried out in a range of adult patients with diabetes. Please see full Prescribing Information for Toujeo at the Sanofi booth 919 in the Exhibit Hall. Steven V. Edelman, MD Director, Taking Control of Your Diabetes (TCOYD ) William H. Polonsky, PhD, CDE President, Behavioral Diabetes Institute Associate Clinical Professor in Psychiatry Bruce W. Bode, MD, FACE Clinician Atlanta Diabetes Associates Atlanta, GA Deborah A. Hinnen, RN, APN, BC-ADM, CDE, FAAN, FAADE Clinician and Diabetes Educator Memorial Hospital University of Colorado Health Colorado Springs, CO 2:45 p.m. 3:30 p.m. A Once-Daily Basal Insulin Option for the Primary Care Management of Diabetes Sponsored by Novo Nordisk Inc. Discuss insulin therapy in optimizing glycemic control and long-acting basal insulin for adult patients with type 2 diabetes. Examine the efficacy and safety data of a long-acting basal insulin therapy. Describe a treatment approach that can be initiated in your adult patients with diabetes. Pablo F. Mora, MD, MSc, FACE, CDE Endocrinologist Diabetes America Plano, TX Clinical Associate Professor Division of Endocrinology University of Texas Southwestern Medical Center Dallas, TX
SUNDAY, JUNE 12 The Importance of Utilizing a Comprehensive Approach When Managing Patients with T2DM T2DM is a complex, progressive disease. As the number of patients with diabetes increases, it is critical to take a closer look at the ongoing challenges of getting patients to glycemic goal despite the availability of medications and detailed treatment guidelines. In this presentation, we will take a closer look at the effects of hyperglycemia prior to diabetes diagnosis, the importance of achieving individualized glycemic goals, the current diabetes treatment landscape, and finally, the potential of multifactorial approaches to treatment. Lawrence Blonde, MD, FACP, FACE Director, Ochsner Diabetes Clinical Research Unit The Frank Riddick Diabetes Institute New Orleans, LA Repatha (evolocumab) Product Overview Sponsored by Amgen Inc. The Repatha (evolocumab) mechanism of action will be reviewed, and an overview of safety data will be provided. The program will also review evidence for the efficacy of Repatha using data from phase 3 randomized, placebo controlled trials, as well as reviewing Repatha dosing and administration. A discussion of appropriate patients will be supplemented by relevant case studies. Harold E. Bays, MD, FTOS, FACC, FACE, FNLA Medical Director/President Louisville Metabolic and Atherosclerosis Research Center, Inc. Louisville, KY 12:30 p.m. 1:30 p.m. Examining Options to Go Further in the Treatment of Type 2 Diabetes Sponsored by Janssen Pharmaceuticals, Inc. This program will cover the following topics regarding a sodium-glucose co-transporter (SGLT-2) inhibitor: the role of the kidney in regulation of hyperglycemia in T2DM; the mechanism of action-mediated inhibition of SGLT-2 in the proximal convoluted tubule of the kidney; key efficacy and safety data from active-controlled clinical trials; important safety information; and a question and answer session. This program is not certified for continuing medical education. James R. Gavin III, MD, PhD Emory University School of Medicine Atlanta, GA John E. Anderson, MD Past President, Medicine & Science American Diabetes Association The Frist Clinic Nashville, TN
12:30 p.m. 1:30 p.m. SGLT-2 Inhibition A Glucuretic Treatment Option for Your Adult Patients With Type 2 Diabetes Sponsored by AstraZeneca The kidney has an important role in the body's regulation of glucose. In patients with type 2 diabetes, the adaptive mechanism to reabsorb glucose in the kidney is thought to become maladaptive. This program will focus on the role of sodium-glucose cotransporter-2 (SGLT-2) inhibition to reduce reabsorption of filtered glucose, lower the renal threshold for glucose, and increase urinary glucose excretion. In addition, the clinical efficacy, safety, and use of an SGLT-2 inhibitor for patients with type 2 diabetes will be reviewed. Serge Jabbour, MD, FACP, FACE Professor of Medicine Director, Division of Endocrinology, Diabetes, & Metabolic Disease Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia, PA 3:00 p.m. 3:45 p.m. Toujeo (Insulin Glargine Injection 300 Units/mL) Clinical Case Studies for Starting Patients with Toujeo Toujeo (insulin glargine injection) 300 Unit/mL is a long-acting basal insulin indicated to improve glycemic control in adult patients with diabetes mellitus. This presentation is intended to provide clinicians with a comprehensive overview of Toujeo and to review case studies of patients staring Toujeo. Pharmacologic features of Toujeo and data from the EDITION clinical trials program will also be presented. Please see full Prescribing Information for Toujeo at the Sanofi booth 919 in the Exhibit Hall. Jeremy Pettus, MD Assistant Professor of Medicine Department of Endocrinology Timothy Gilbert, MD Practicing Endocrinologist Imperial Health Lake Charles, LA 3:00 p.m. 3:45 p.m. A Treatment Option for Patients Who Are Severely Insulin Resistant Sponsored by Lilly USA, LLC 2016 The program is about a concentrated human insulin indicated to improve glycemic control in patients with diabetes requiring >200 units of insulin a day. Hear about the product profile, patients who may benefit from it, clinical results and titration-to-target algorithms, and the dedicated injection device. Robert C. Hood, MD, FRCPC, FACE Director, Endocrine Clinic of Southeast Texas Beaumont, TX
MONDAY, JUNE 13 The Efficacy Mirage in Type 2 Diabetes Why Do Clinical Trial Results Disappear in Real-World Practice? Sponsored by Intarcia Therapeutics, Inc. Since 2005, nearly 40 new treatments have been approved for type 2 diabetes (T2D) with some of these agents showing impressive clinical trial efficacy. Despite this, less than half of the patient population achieves HbA1c goal, and morbidity and mortality rates are at an alarming level. Recent data have demonstrated that outcomes in the real-world fall far short of the efficacy seen in clinical trials. Adherence and persistence are key drivers behind this disconnect with current agents delivering adherence rates of less than 50% and persistence rates of less than 25% over a year. This presentation will discuss the current state of diabetes and will challenge attendees to think differently about management approaches so that in the future we can finally deliver the improved patient outcomes that we have not been able to recognize with current therapies. Steven V. Edelman, MD Director, Taking Control of Your Diabetes (TCOYD ) William H. Polonsky, PhD, CDE President, Behavioral Diabetes Institute Associate Clinical Professor in Psychiatry Rationale for an Oral Treatment for Type 2 Diabetes that Targets the Incretin Hormones Sponsored by Merck Understand the incretin effect and its impact on islet function and hepatic glucose production in T2DM. Discuss an oral treatment that targets the incretin hormones and helps to improve glycemic control in T2DM. Helena W. Rodbard, MD, FACP, MACE Endocrine and Metabolic Consultants Past President, American Association of Clinical Endocrinologists Past President, American College of Endocrinology Rockville, MD